In an ongoing phase I/II study of durvalumab (NCT02484404) in combination with either the PARP inhibitor, olaparib, or the VEGFR inhibitor, cediranib, there was 1 PR in 9 evaluable ovarian cancer patients lasting >6 months with the combination of durvalumab and olaparib and 1 PR in 5 evaluable ovarian cancer patients treated with durvalumab and cediranib [29]. The gene discussed is KDR; the disease is ovarian cancer.